Ohio AG calls for new PBM transparency law, saying state 'hired a fox to guard the henhouse'

Ohio sign
Ohio's attorney general has released a four-point policy proposal to increase pharmacy benefit manager transparency. (fotoguy22/Getty)

Ohio’s attorney general is continuing his war on pharmacy benefit managers, this time by proposing a multistep plan to improve transparency and lower drug costs. 

AG Dave Yost announced the four-piece proposal and called for swift action from the state’s legislature to shine greater light on PBM contracts in Medicaid and cut down on centralization. 

Yost has been a loud critic of PBMs following the release of a report last summer in his previous role as state auditor that highlighted spread pricing practices in Medicaid. PBMs operating in Ohio Medicaid earned nearly $225 million through spread pricing between April 2017 and March 2018, the report found. 

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

The state cancelled all PBM contracts in Medicaid that use spread pricing as a result. 

“When state agencies entered into these nebulous deals with PBMs, they unknowingly hired a fox to guard the henhouse,” Yost said in a statement. “But he was a smart fox. He didn’t kill the chickens—he helped himself to the eggs.” 

RELATED: CVS, Express Scripts provide a rare moment of transparency on rebate profits 

Yost’s proposal calls for: 

  • Drug purchases in the state to be conducted under a master PBM contract that is administered by a single contact point,
  • Ohio’s Auditor of State to have full power to review all PBM contracts, purchases and payments,
  • PBMs to operate as fiduciaries, and
  • The state to prohibit nondisclosure agreements on drug pricing.

Yost said that these provisions would shine a light on what PBMs are doing without creating additional bureaucracies and administrative inefficiencies. The goal is for a “market-based solution” to drive greater transparency, he said. 

Yost has also taken legal action against Optum, suing to claw back $16 million in what he says are drug overpayments the PBM charged to Ohio’s Bureau of Worker’s Compensation. 

Optum said the allegations are “without merit.” 

Suggested Articles

Medicare Part D beneficiaries could see their out-of-pocket costs go up next year before they reach catastrophic coverage, a new analysis shows.

California health officials have released their first report on the price hikes drug companies sought to shield.

Nancy Pelosi's drug prices plan would save Medicare an estimated $345 billion over seven years, according to the Congressional Budget Office.